Literature DB >> 34286451

Deciphering hypertrophic cardiomyopathy with electrocardiography.

Thomas Gossios1,2,3, Konstantinos Savvatis4, Thomas Zegkos5, Dimitrios Ntelios5, Pavlos Rouskas5, Despoina Parcharidou5, Haralambos Karvounis5, Georgios K Efthimiadis5.   

Abstract

The comprehensive assessment of patients with hypertrophic cardiomyopathy is a complex process, with each step concurrently focusing on confirmation of the diagnosis, differentiation between sarcomeric and non-sarcomeric disease (phenocopy), and prognostication. Novel modalities such as genetic testing and advanced imaging have allowed for substantial advancements in the understanding of this condition and facilitate patient management. However, their availability is at present not universal, and interpretation requires a high level of expertise. In this setting, electrocardiography, a fast and widely available method, still retains a significant role in everyday clinical assessment of this population. In our review, we follow a stepwise approach for the interpretation of each electrocardiographic segment, discussing clinical implications of electrocardiographic patterns in sarcomeric disease, their value in the differential diagnosis from phenocopies, and impact on patient management. Outlining the substantial amount of information to be obtained from a simple tracing, we exhibit how electrocardiography is likely to remain an integral diagnostic tool in the future as well.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Arrhythmia; Cardiac hypertrophy; Electrocardiography; Hypertrophic cardiomyopathy; Myocardial fibrosis; Sudden cardiac death

Mesh:

Year:  2021        PMID: 34286451     DOI: 10.1007/s10741-021-10147-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  90 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy.

Authors:  Sang-Eun Lee; Jin-Kyu Park; Jae-Sun Uhm; Jong Youn Kim; Hui-Nam Pak; Moon-Hyoung Lee; Boyoung Joung
Journal:  Heart       Date:  2017-04-20       Impact factor: 5.994

Review 3.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.

Authors:  Oliver P Guttmann; M Shafiqur Rahman; Constantinos O'Mahony; Aris Anastasakis; Perry M Elliott
Journal:  Heart       Date:  2013-09-07       Impact factor: 5.994

4.  Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging.

Authors:  Sanjay Sivalokanathan; Tarek Zghaib; Gabriela V Greenland; Nestor Vasquez; Shibani M Kudchadkar; Effrosyni Kontari; Dai-Yin Lu; Ketty Dolores-Cerna; Rob J van der Geest; Ihab R Kamel; Jeffrey E Olgin; Theodore P Abraham; Saman Nazarian; Stefan L Zimmerman; M Roselle Abraham
Journal:  JACC Clin Electrophysiol       Date:  2018-12-26

5.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Anais Hausvater; Mark S Link; Patrick Abt; William Gionfriddo; Wendy Wang; Hassan Rastegar; N A Mark Estes; Martin S Maron; Barry J Maron
Journal:  Circulation       Date:  2017-09-15       Impact factor: 29.690

Review 6.  Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Authors:  Kaivan Vaidya; Christopher Semsarian; Kim H Chan
Journal:  Heart Lung Circ       Date:  2017-05-23       Impact factor: 2.975

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

8.  Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram.

Authors:  Christopher J McLeod; Michael J Ackerman; Rick A Nishimura; A Jamil Tajik; Bernard J Gersh; Steve R Ommen
Journal:  J Am Coll Cardiol       Date:  2009-07-14       Impact factor: 24.094

9.  CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Authors:  Theano Papavassiliu; Tjeerd Germans; Stephan Flüchter; Christina Doesch; Anton Suriyakamar; Dariusch Haghi; Tim Süselbeck; Christian Wolpert; Dietmar Dinter; Stefan O Schoenberg; Albert C van Rossum; Martin Borggrefe
Journal:  J Cardiovasc Magn Reson       Date:  2009-09-09       Impact factor: 5.364

10.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.

Authors:  Konstantinos C Siontis; Jeffrey B Geske; Kevin Ong; Rick A Nishimura; Steve R Ommen; Bernard J Gersh
Journal:  J Am Heart Assoc       Date:  2014-06-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.